Overall, we uncovered an HMGA2/IGF2BPs/IGF2/IGF1R/AKT-mTOR functional pathway that characterizes CDS and renders the tumor particularly sensitive to combined treatment with trabectedin and AKT/mTOR inhibitors (schematically represented in Fig. 5D). This evidence concerns the gene IGF1R and neoplasm.